Timeline of Antibody-Drug Conjugate Deals & Transactions in 2023

January

Synaffix, AMGEN	$2B (L)
Synaffix, Hummingbird Bioscience	$150M (L)
DualityBio, adcendo	* (L)
Mersana Therapeutics, Merck	$830M (L)
Mersana Therapeutics, GSK	$1.46B (L)
Mersana Therapeutics, Janssen	$1.04B (L)
immunome, abbvie	$120M (L)

February

NONA Biosciences, MYTHIC Therapeutics	* (L)
Synaffix, Chong Kun Dang Pharm. (Seoul, Korea)	$132M (L)
XDC The Bioconjugation Leader, CIDARA Therapeutics	* (DA)
KeyMed Biosciences, AstraZeneca	$1.2B (L)
MEGALITH Pharmaceuticals, CORBUS Pharmaceuticals	$693M (L)

March

CIDARA Therapeutics, Janssen	$685M (C)
Synaffix, MacroGenics	$2.2B (L)
CytomX, moderna	$1.24B (L)
CytomX, REGENERON	$2.03B (C)
Seagen, Pfizer	$43B (A)
immunogen, VERTEX	$352M (L)
immunogen, GILEAD	* (C)

April

ARS Pharma, araris	* (AP)
TUBULIS, Bristol Myers Squibb	$1.03B (L)
innate pharma, Takeda	$415M (L)
DualityBio, BIONTECH	$1.67B (L)
PYRAMID Biosciences, GeneQuantum Healthcare	$1.02B (L)

May

magenta Therapeutics, DIANTHUS Therapeutics	$170M (M)
Eisai, BlissBio	$2B (DA)
FORTIS Therapeutics, FibroGen	$200M (L)
LaNova, AstraZeneca	$600M (L)
SONY, astellas	* (C)
Synaffix, Lonza	$174M (A)
THOUSAND OAKS, GeneQuantum Healthcare	$28M (C)
Apexigen, PYXIS ONCOLOGY	$16M (A)
ONCOMATRIX, Tube Pharma	* (A)

June

July

ETX Emergence Therapeutics, Lilly	$12M (A)
BIOCYTOGEN, PHEON Therapeutics	* (L)
AIMEDBIO, GeneQuantum Healthcare	* (C)
DualityBio, BeiGene	$1.3B (C)
XDC The Bioconjugation Leader	* (S)
NONA Biosciences, DualityBio	* (C)
ImmunoBiochem Corporation, immunogen	* (L)
inxmed, GeneQuantum Healthcare	* (L)
LOTTE BIOLOGICS, KANAPH	* (C)

August

DualityBio, BIONTECH	* (C)
immunogen, Takeda	$34M (L)

September

ETX Emergence Therapeutics, Lilly	$805M (A)
nurix, Seagen	$3.46B (C)
Synaffix, ablbio	* (L)

October

Lonza, 宜联生物 MediLink Therapeutics, BIONTECH	* (C)
Synaffix, Sotio	$1.07B (L)
Lonza, XDC The Bioconjugation Leader, HKSTP	$740M (L)
mablink, Lilly	* (C)
Hummingbird Bioscience, ENDEAVOR BioMedicines	* (A)
Daiichi-Sankyo, MERCK	$430M (L)
KELUN-BIOTECH 科伦博泰, MERCK	$16.5B (C)
HANSOH Pharma, GSK	* (C)
HENGRUI, MERCK	$1.57B (L)
	$1.67B (C)

November

ORUM Therapeutics, Bristol Myers Squibb	$180M (A)
Daiichi-Sankyo	* (M)
TAIHO 大鹏薬品, araris	* (C)
GeneQuantum Healthcare, NONA Biosciences	* (C)
WuXi Biologics Global Solution Provider, MyricxBio	* (L)
TUBULIS, ONCOTEC Pharma Produktion	* (C)
AVIDITY Biosciences, Bristol Myers Squibb	$2.3B (C)
immunogen, abbvie	$10.01B (A)
AIMEDBIO, GeneQuantum Healthcare	* (C)

December

Synaffix, Innovent 信达生物制药	* (L)
SYSTIMMUNE, Bristol Myers Squibb	$8.4B (C)
C4 Therapeutics, MERCK	$2.5B (L)
BIOCYTOGEN, ONA Therapeutics	* (L)
NONA Biosciences, Pfizer	$1.103B (L)
HANSOH Pharma, GSK	$1.685B (L)
诗健生物 Escugen, inxmed	* (L)
Janssen, LCB LegoChemBio	$1.7B (L)
DONG-A ST, AbTis	• (A)

C = Collboration; L = Licensing; A = Aquisition; M = Merger; AP = Asset Purchase; DA = Development Agreement; S = Spinoff

Notes: 2023 YTD as of December 26th; * Deal value not publicly disclosed
Sources: DeciBio Research and Internal Databases; DeciBio TheraTrack

DeciBio